Foghorn therapeutics to present clinical and pre-clinical data from multiple programs across its diverse pipeline at aacr-nci-eortc international conference

Cambridge, mass., oct. 04, 2023 (globe newswire) -- foghorn® therapeutics inc. (nasdaq: fhtx), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its brg1/brm inhibitor fhd-286, pre-clinical data for its selective ep300 program, and pre-clinical data for its brd9 degrader fhd-609, will be presented at the aacr-nci-eortc international conference. the conference will be held october 11–15, 2023, in boston, massachusetts.
FHTX Ratings Summary
FHTX Quant Ranking